Pharmacological Medical Treatment of Epilepsy in Patients with Dementia: A Systematic Review.


Journal

Current Alzheimer research
ISSN: 1875-5828
Titre abrégé: Curr Alzheimer Res
Pays: United Arab Emirates
ID NLM: 101208441

Informations de publication

Date de publication:
2021
Historique:
received: 11 03 2021
revised: 25 06 2021
accepted: 08 09 2021
pubmed: 27 11 2021
medline: 2 4 2022
entrez: 26 11 2021
Statut: ppublish

Résumé

Patients with dementia have an increased risk of developing epilepsy, especially in patients with vascular dementia and Alzheimer's disease. In selecting the optimal anti- epileptic drug (AED), the possible side effects such as drowsiness and worsening of cognitive function should be taken into consideration, together with co-morbidities and type of epilepsy. The current systematic review investigates the efficacy, tolerability, and changes in cognitive function after administration of AED in patients with dementia and epilepsy. We searched six databases, including MEDLINE and CENTRAL, checked reference lists, contacted experts, and searched Google Scholar to identify studies reporting randomized trials. Studies identified were independently screened, data extracted, and quality appraised by two researchers. A narrative synthesis was used to report findings. We included one study with 95 patients with Alzheimer's disease randomized to either levetiracetam, lamotrigine, or phenobarbital. No significant differences were found for efficacy, but patients receiving levetiracetam showed an improvement in mini-mental state examination scores and had fewer adverse events. High-quality evidence in the form of randomized controlled trials to guide clinicians in choosing an AED in patients with dementia and concomitant epilepsy remains scarce. However, levetiracetam has previously been shown to possibly improve cognition in patients with both mild cognitive impairment and Alzheimer's disease, is better tolerated in the elderly population, and has no clinically relevant interaction with either cholinesterase inhibitors or NMDA receptor antagonists.

Sections du résumé

BACKGROUND
Patients with dementia have an increased risk of developing epilepsy, especially in patients with vascular dementia and Alzheimer's disease. In selecting the optimal anti- epileptic drug (AED), the possible side effects such as drowsiness and worsening of cognitive function should be taken into consideration, together with co-morbidities and type of epilepsy.
OBJECTIVE
The current systematic review investigates the efficacy, tolerability, and changes in cognitive function after administration of AED in patients with dementia and epilepsy.
METHODS
We searched six databases, including MEDLINE and CENTRAL, checked reference lists, contacted experts, and searched Google Scholar to identify studies reporting randomized trials. Studies identified were independently screened, data extracted, and quality appraised by two researchers. A narrative synthesis was used to report findings.
RESULTS
We included one study with 95 patients with Alzheimer's disease randomized to either levetiracetam, lamotrigine, or phenobarbital. No significant differences were found for efficacy, but patients receiving levetiracetam showed an improvement in mini-mental state examination scores and had fewer adverse events.
CONCLUSION
High-quality evidence in the form of randomized controlled trials to guide clinicians in choosing an AED in patients with dementia and concomitant epilepsy remains scarce. However, levetiracetam has previously been shown to possibly improve cognition in patients with both mild cognitive impairment and Alzheimer's disease, is better tolerated in the elderly population, and has no clinically relevant interaction with either cholinesterase inhibitors or NMDA receptor antagonists.

Identifiants

pubmed: 34825872
pii: CAR-EPUB-119083
doi: 10.2174/1567205018666211126121529
doi:

Substances chimiques

Anticonvulsants 0
Levetiracetam 44YRR34555
Lamotrigine U3H27498KS

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

689-694

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Christian S Musaeus (CS)

Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet,Denmark.

Christer Nilsson (C)

Department of Neurology and Rehabilitation Medicine, Skåne University Hospital, Lund,Sweden.

Chris Cooper (C)

Department of Clinical Educational and Health Psychology, University College London, London,United Kingdom.

Milica G Kramberger (MG)

Department of Neurology, Center for Cognitive Impairments, University Medical Center Ljubljana, and Medical Faculty, University of Ljubljana, Ljubljana,Slovenia.

Ana Verdelho (A)

Department of Neurosciences and Mental Health, CHLNorte-Hospital de Santa Maria, IMM, ISAMB, Faculty of Medicine, University of Lisbon, Lisbon,Portugal.

Elka Stefanova (E)

Medical Faculty, Neurology Clinic CCS, University of Belgrade, Beograd,Serbia.

Dorota Religa (D)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Neo, Stockholm,Sweden.

Gunhild Waldemar (G)

Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet,Denmark.

Kristian S Frederiksen (KS)

Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet,Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH